Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Study Demonstrating Lurasidone Is Effective In Patients With Schizophrenia Published In The Journal Of Clinical Psychiatry
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced that positive results from a phase 2 clinical trial for lurasidone in the treatment of patients with schizophrenia have been published in The Journal of Clinical Psychiatry. This six-week, randomized, double-blind, multicenter, placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a single fixed dose of lurasidone 80 mg/day versus placebo. Lurasidone 80 mg/day produced statistically significant improvement versus placebo in both primary and secondary efficacy assessments at all study visits starting at day 3. In addition, lurasidone was generally well-tolerated and was associated with weight and metabolic changes that were similar to placebo.
generic viagra online
Alabama Dept. of Public Health Proposes Civil Penalty Against Company For Failing To Properly Maintain Security, Accountability Of Radioactive s
The Alabama Department of Public Health has proposed a $650 civil penalty against
News of the day
In Pediatric Patients Sleep Disorders Are Largely Underdiagnosed
Primary care pediatricians may be under-diagnosing sleep disorders in children and teens, according to a research abstract presented on June 8 at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
Medical Devices

U.S. Swine Flu Cases Reach One Million

The Associated Press/Washington Post reported that U.S. health officials on Thursday said they believe as many as 1 million Americans have been infected with H1N1 and "6 percent or more of some urban populations are infected." The estimates were based upon survey data collected by health officials and mathematical modeling. The article also notes that "as many as 60 million doses of vaccine to protect against the new virus could be ready by September, said Robin Robinson, an official with the federal agency that oversees vaccine manufacture and distribution." But others at the meeting said "that prediction seemed a bit optimistic" (Stobbe, 6/26). According to the Los Angeles Times, Lyn Finelli, a flu surveillance official with the Centers for Disease Control and Prevention, told members of a vaccine advisory committee that while there are nearly 28,000 laboratory-confirmed U.S. cases of the virus have been reported to the CDC, "standard models of viral spread indicate that many times that number have been infected." The seasonal flu typically infects between 15 million to 60 million Americans annually. By this time of year, "[t]he normal seasonal flu virus has virtually disappeared from this country, as would be expected. But the novel H1N1 virus is continuing to spread, and now accounts for 98% of all cases" (Los Angeles Times, 6/25). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009